Oric Pharmaceuticals (NASDAQ:ORIC) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Oric Pharmaceuticals (NASDAQ:ORIC) in a research note issued to investors on Thursday,Benzinga reports. They currently have a $25.00 price objective on the stock.

Other equities analysts also recently issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Thursday, January 22nd. Citigroup raised their price objective on Oric Pharmaceuticals from $16.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Oric Pharmaceuticals in a research note on Monday, March 9th. Wedbush decreased their target price on Oric Pharmaceuticals from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Piper Sandler began coverage on Oric Pharmaceuticals in a research note on Wednesday, January 7th. They issued an “overweight” rating and a $22.00 price target on the stock. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.90.

Oric Pharmaceuticals Price Performance

Shares of ORIC stock opened at $8.89 on Thursday. The company has a fifty day moving average price of $11.56 and a two-hundred day moving average price of $11.30. Oric Pharmaceuticals has a one year low of $3.90 and a one year high of $14.93. The stock has a market cap of $892.20 million, a P/E ratio of -5.85 and a beta of 1.36.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings data on Monday, February 23rd. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.04. As a group, equities research analysts anticipate that Oric Pharmaceuticals will post -2.17 EPS for the current fiscal year.

Insider Transactions at Oric Pharmaceuticals

In other news, CFO Dominic Piscitelli sold 52,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $13.51, for a total transaction of $702,520.00. Following the completion of the sale, the chief financial officer owned 68,148 shares in the company, valued at $920,679.48. The trade was a 43.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 6.82% of the stock is owned by company insiders.

Hedge Funds Weigh In On Oric Pharmaceuticals

Large investors have recently made changes to their positions in the company. Orbimed Advisors LLC boosted its stake in Oric Pharmaceuticals by 305.0% in the 3rd quarter. Orbimed Advisors LLC now owns 3,641,756 shares of the company’s stock valued at $43,701,000 after purchasing an additional 2,742,475 shares during the period. Paradigm Biocapital Advisors LP bought a new position in Oric Pharmaceuticals during the 4th quarter worth $19,642,000. State Street Corp lifted its holdings in shares of Oric Pharmaceuticals by 77.1% during the fourth quarter. State Street Corp now owns 4,258,397 shares of the company’s stock worth $34,834,000 after buying an additional 1,854,458 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Oric Pharmaceuticals by 48.8% in the third quarter. Vanguard Group Inc. now owns 4,650,138 shares of the company’s stock valued at $55,802,000 after acquiring an additional 1,525,445 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Oric Pharmaceuticals by 3,646.1% in the second quarter. JPMorgan Chase & Co. now owns 1,335,448 shares of the company’s stock valued at $13,555,000 after acquiring an additional 1,299,799 shares during the period. Institutional investors own 95.05% of the company’s stock.

Trending Headlines about Oric Pharmaceuticals

Here are the key news stories impacting Oric Pharmaceuticals this week:

• Positive Sentiment: Unusually large call buying — traders bought roughly 2,266 call contracts (a >2,000% increase vs. average), signaling speculative bullish interest or potential short‑covering that can amplify intraday upside.
• Positive Sentiment: HC Wainwright reaffirmed a “buy” and reiterated a $25 price target, providing institutional support and a high potential upside narrative for growth investors. HC Wainwright reaffirmation
• Neutral Sentiment: Oric announced selection of the recommended Phase 3 dose (RP3D) for rinzimetostat in combination with darolutamide and will advance the HIMALAYAS‑1 global Phase 3 study — a clinical program advancement that is structurally positive but comes with execution and safety readout risk. Phase 3 RP3D selection
• Negative Sentiment: Multiple reports noted the stock plunged after the Phase 1b update showed safety/tolerability issues at higher doses (investor reaction included steep intraday and after‑hours declines), raising concerns about dose optimization and commercial positioning. Yahoo coverage of drop Investing.com coverage
• Negative Sentiment: Wedbush trimmed its price target from $20 to $17 (still an “outperform”), a modestly less bullish signal that reflects tighter expectations around valuation given the recent safety/dose information. Wedbush price target change

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.